Establishing an international consortium for gene discovery and clinical research for Congenital Muscle Diseases
- Version 214
- Download 0
- File Size 4.00 KB
- File Count 1
- Create Date 16 October 2015
- Last Updated 1 October 2019
Location: Heemskerk
Organisers: Assoc. Prof. Daniel MacArthur (Boston, USA); Prof. Carsten Bonnemann (Bethesda, USA); Assoc. Prof. James J. Dowling (Toronto, Canada); Dr. Jocelyn Laporte (Strasbourg, FR)
Participants: Alan Beggs (Boston, USA), Gisele Bonne (Paris, FR), Carsten Bonnemann (Bethesda, USA), Sandra Donkervoort (Bethesda, USA), James Dowling (Toronto, CAN), Victor Dubowitz (London, UK), Michael Goldberg (RYR1 Foundation, USA), Morton Goldberg (RYR1 Foundation, USA), Yann Herault (Paris, FR), Mert Karakaya (Koln, GER), Jocelyn Laporte (Strasbourg, FR), Anne Lennox (MTM Trust, UK), Daniel MacArthur (Boston, USA), Edoardo Malfatti (Paris, FR), Katherine Mathews (Iowa City, USA), Marina Mora (Milan, IT), Ichizo Nishino (Tokyo, JP), Emily Oates (via WebEx) (Sydney, AU), Anne Rutkowski (CureCMD, USA), Melanie Spring (MTM Trust, UK), Nicol Voermans (Nijmegen, NL), Jodi Warman (Ottawa, CAN), Tobias Willer (Regeneron, USA), Hui Xiong (Beijing, CH), Irina Zaharieva (London, UK), Edmar Zanoteli (Sao Paolo, BR)
This workshop was sponsored by the ENMC members, the ENMC Company Forum (Amicus, Genzyme, PTC and Santhera), Foundation Building Strength, Myotubular Trust and Cure CMD.
Description: The 214th ENMC workshop entitled “establishing an international consortium for gene discovery and clinical research for congenital muscle diseases” took place from the 16th-18th of October 2015 in Heemskerk, Netherlands. A multidisciplinary group of 26 participants took part in this workshop, including 22 clinical and basic science researchers from 11 different countries (France, the UK, Japan, Canada, Brazil, China, Turkey, Italy, the Netherlands, Australia, and the USA) and 4 patient representatives (Myotubular Trust, RYR1 Foundation and CureCMD).
The participants of the 214th ENMC workshop
Background: Congenital muscle diseases are a group of conditions encompassing the congenital myopathies (CM) and the congenital muscular dystrophies (CMD). Individually, these are very rare conditions, but collectively they represent a major subset of neuromuscular diseases across the lifespan. CM/CMDs are associated with significant disabilities and early mortality in most instances. While there is good evidence that subtype specific supportive care measures improve symptomatology, there are currently no cures or significant disease modifying specific therapies. A key existing barrier to clinical care and therapy development for CM/CMDs is a lack of genetic diagnosis in the majority of cases. This is due in some cases to inadequate testing of known CM/CMD genes and in others to currently unknown/unsolved genetic causes. At present, there are approximately 45 CM/CMD disease genes, and this likely represents 50% of the predicted genetic disease burden. There is therefore a great need (a) for better access to and application of clinical testing of the known CM/CMD genes and (b) for concerted gene discovery efforts aimed at identifying the remaining genetic causes of disease, each one of which will be very rare, necessitating an international collaborative approach to their discovery.
Aim of this workshop: The best way to address the barriers created by lack of knowledge of the genetic bases of CM/CMD is to have the experts and stake holders in this field working together. Therefore, the primary goal of this workshop was to accomplish this by establishing a consortium for the study of the genetics of congenital muscle diseases. Within this overarching aim, additional goals included defining the mission of the consortium and the initial projects for the group.
What was achieved: In the first half of the workshop, we defined the existing independent efforts at gene discovery for CM/CMD, discussed infrastructure that currently exists for these efforts (both for CM/CMD and for rare genetic diseases in general), and learned about existing networks related to other disease groups. In the second half of the workshop, we formally established an international CM/CMD consortium, and decided upon additional prospective members to be invited after the conclusion of the meeting. We agreed that the mission statement of this consortium is “all individuals with CM/CMD deserve to have defined the genetic basis of their disease”, and proposed to begin addressing this mission through 3 initial efforts.
Key deliverables: These efforts, to be promoted by working groups within the consortium, represent the key deliverables of the workshop, and include (1) development of a clinical genetic testing platform for individuals without current access to testing, (2) creation of a data sharing platform for existing cohorts, and (3) development of a common phenotyping platform. The goal is that the working groups will have formulated plans for each of these initiatives within 8 weeks of the meeting. The secondary goal is that these deliverables will be successfully implemented within 18 months of the workshop, whereupon a second meeting of the consortium will take place.
A full report is published in Neuromuscular Disorders (pdf)
Groups discussions on Sunday
ENMC
Lt. generaal van Heutszlaan 6
3743 JN BAARN
The Netherlands
+ 31- 35-5480481
enmc@enmc.org
We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy